Avalyn Pharma Inc. Common Stock
AVLN | NASDAQ
$25.63
-$0.08 (-0.31%)
At close: Oct 30, 2026, 4:00 PM ET
$23.20
-$2.43 (-9.48%)
Pre-market:
Nov 2, 2026, 7:45 AM ET
Company Profile
Avalyn Pharma Inc. operates as a biopharmaceutical firm currently in its clinical development phase. The company's primary focus is on creating inhaled pharmaceutical products to manage rare lung conditions, including pulmonary fibrosis and various other interstitial lung diseases (ILDs). Richard Glenn Vincent, Mark W. Surber, and Michael J. Kamdar co-founded the enterprise on May 27, 2011, and its corporate headquarters are situated in Boston, Massachusetts.
Key Executives
| Name | Position |
|---|---|
| Lyn Baranowski | CEO, President & Director |
| Melissa Rhodes DABT | Chief Operating Officer |
| Adam Golden | General Counsel & Head of Business Development |
| Cassie Saitow | Senior Director of IR & Corporate Communications |
| Craig Conoscenti | Senior Vice President of Clinical Development |
| Douglas R. Carlson | CFO & Chief Business Officer |
| Howard Lazarus | Chief Medical Officer |
| James Bishop | Senior Vice President of Business Operations |
| Michelle Patterson | Senior Vice President of Corporate Planning & Portfolio Strategy |
| Stephen Pham | Senior Vice President of Product Development |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Sep 17, 2026 | 4 | Filing |
| Sep 17, 2026 | 3 | Filing |
| Sep 16, 2026 | 8-K | Current Report |
| Aug 14, 2026 | SC 13G | Statement of acquisition of beneficial ownership b... |
| Aug 12, 2026 | 10-Q | Quarterly Report |
| Aug 12, 2026 | 8-K | Current Report |
| Aug 11, 2026 | SC 13G | Statement of acquisition of beneficial ownership b... |
| Aug 06, 2026 | SC 13G/A | [Amend] Statement of acquisition of beneficial own... |
| Jul 01, 2026 | 8-K | Current Report |
| Jun 17, 2026 | 8-K | Current Report |
Avalyn Pharma Inc. Common Stock
| Country | United States |
| IPO Date | Apr 30, 2026 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 55 |
| CEO | Lyn Baranowski |
Contact Details
105 W First St. Boston Boston,
Massachusetts 02127 United States
Stock Details
| Ticker Symbol | AVLN |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001540171 |
| CUSIP Number | 05348Y105 |
| ISIN Number | US05348Y1055 |
| SIC Code | 2834 |
Recent News
- 1 month ago / globenewswire.comAvalyn Publishes Phase 1 Data Highlighting AP02's Lung-Targeted Delivery and Encouraging Safety Profile
- 2 months ago / globenewswire.comAvalyn Appoints Robert J. Meyer, MD, to its Board of Directors
- 2 months ago / globenewswire.comAvalyn Presents New Data at ERS Congress 2026 Supporting AP01 Lung Distribution and Patient-Centered Trial Design in Pulmonary Fibrosis
- 2 months ago / globenewswire.comAvalyn Announces Multiple Presentations at the European Respiratory Society International Congress 2026
- 3 months ago / globenewswire.comAvalyn Reports Second Quarter 2026 Financial Results and Recent Business Highlights
- 5 months ago / marketbeat.comAvalyn Pharma Outlines Inhaled Fibrosis Push After IPO, With Pivotal Data Ahead
- 5 months ago / globenewswire.comAvalyn Reports First Quarter 2026 Financial Results and Recent Business Highlights
- 6 months ago / globenewswire.comAvalyn Announces Additional Long-term Data on AP01, Inhaled Pirfenidone, for the Treatment of Pulmonary Fibrosis to be Presented at the European Alliance of Associations for Rheumatology 2026
- 6 months ago / globenewswire.comAvalyn to Present Patient-Centered Research on AP01 Delivery and Supportive Care Experiences at American Thoracic Society 2026 International Conference
- 6 months ago / globenewswire.comAvalyn Announces Closing of Initial Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares
Add to Watchlist
Select watchlists to add or remove AVLN